Renal Phosphate Wasting Disorders: X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO)
This session will include case studies of X-Linked Hypophosphatemia (XLH) as well as diagnosis and management of XLH and Tumor-Induced Osteomalacia (TIO).
- XLH is a rare, hereditary, progressive, and lifelong skeletal disorder mediated by increased fibroblast growth factor 23 (FGF23) activity that causes renal phosphate wasting. This leads to chronic hypophosphatemia, resulting in poor skeletal, muscular, and dental health and impaired physical function
- TIO, also known as oncogenic osteomalacia, is an ultrarare, acquired disorder in which tumors that express the phosphaturic hormone FGF23 cause chronic hypophosphatemia, muscle weakness, and osteomalacia
- Unlike XLH, TIO patients typically have a history of normal phosphate levels and usually present in adulthood with symptoms of pain, muscle weakness, and fatigue that may be severe and progressive